These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9457287)

  • 1. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer.
    Van der Poel HG; Van Balken MR; Schamhart DH; Peelen P; de Reijke T; Debruyne FM; Schalken JA; Witjes JA
    Urology; 1998 Jan; 51(1):44-50. PubMed ID: 9457287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human complement factor H related protein test for monitoring bladder cancer.
    Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
    J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
    Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
    Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer.
    Schamhart DH; de Reijke TM; van der Poel HG; Witjes JA; de Boer EC; Kurth K; Schalken JA
    Eur Urol; 1998 Aug; 34(2):99-106. PubMed ID: 9693243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can sensitivity of voided urinary cytology or bladder wash cytology be improved by the use of different urinary portions?
    Mungan NA; Kulacoglu S; Basar M; Sahin M; Witjes JA
    Urol Int; 1999; 62(4):209-12. PubMed ID: 10567884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
    Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
    Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H; Hall R; Mazeman E; Blumenstein BA
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer.
    van der Poel HG; Witjes JA; van Stratum P; Boon ME; Debruyne FM; Schalken JA
    Urology; 1996 Sep; 48(3):357-64. PubMed ID: 8804485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma.
    Badalament RA; Hermansen DK; Kimmel M; Gay H; Herr HW; Fair WR; Whitmore WF; Melamed MR
    Cancer; 1987 Oct; 60(7):1423-7. PubMed ID: 3304614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Bard Trak test with voided urine cytology in the diagnosis and follow-up of bladder tumors.
    Chautard D; Daver A; Bocquillon V; Verriele V; Colls P; Bertrand G; Soret JY
    Eur Urol; 2000 Dec; 38(6):686-90. PubMed ID: 11111185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.
    van Rhijn BW; van der Poel HG; Boon ME; Debruyne FM; Schalken JA; Witjes JA
    Urology; 2000 Mar; 55(3):363-7. PubMed ID: 10699611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
    Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
    J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
    Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
    Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
    Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
    Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer.
    Leyh H; Mazeman E
    Eur Urol; 1997; 32(4):425-8. PubMed ID: 9412800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
    Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
    Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.